 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eloxx Pharmaceuticals (NASDAQ:ELOX  Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX  Get Free Report) are both small-cap medical companies, but which is the better...

Comparing Eloxx Pharmaceuticals (NASDAQ:ELOX) & BioCryst Pharmaceuticals (NASDAQ:BCRX)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA

Podocyte Exact Morphology Procedure Results

 Podocyte Exact Morphology Procedure Results

ELX-02 treatment improved podocyte foot process effacement in all three patients by an...

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Novozymes A/S (OTCMKTS:NVZMY  Get Free Report) and Eloxx Pharmaceuticals (NASDAQ:ELOX  Get Free Report) are both basic materials companies, but which is the better investment? We will...

Financial Contrast: Novozymes A/S (OTCMKTS:NVZMY) and Eloxx Pharmaceuticals (NASDAQ:ELOX)

Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three...

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals (NASDAQ:ELOX  Get Free Report) and Ocugen (NASDAQ:OCGN  Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, ...

Critical Analysis: Eloxx Pharmaceuticals (NASDAQ:ELOX) vs. Ocugen (NASDAQ:OCGN)

All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport ...

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Shares of biopharmaceutical company Eloxx Pharmaceuticals (NASDAQ:ELOX) are on the rise today after it announced positive results from a Phase 2 st...
Shares of biopharmaceutical company Eloxx Pharmaceuticals (NASDAQ:ELOX) are on the rise today after it announced positive results from a Phase 2 ...

Eloxx Pharma (NASDAQ:ELOX) Rises On Promising Phase 2 Data In Alport Syndrome

WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the Hearings Panel) of The Nasdaq Stock Market...

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Key Points Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx ... Read more

Key Points

Shares of Elox surged almost 100% after receiving an increased price target from Oppenheimer and published preclinical data demonstrating activity against ...

This Small Cap Stock Surged Over 100%

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.

Market Cap	$3.11M
Volume (M)	12,135.00
52-Wk High	$10.90
52-Wk Low	$0.94

Current Price	$0.99
Prev Close	$1.10
Open	$1.11
Dividend Yield	0.00%
50-Day Moving Average	$2.00
Beta	0.77
Avg. Volume	14,239.29
PE Ratio	-0.11

52-Week High	$10.90
52-Week Low	$0.94
Market Capitalization	$3.11M
EPS	-$9.06
Price to Book	-0.11
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.75

ELOX Eloxx Pharmaceuticals Inc

About

Feed

News

Sentiment

Fundamentals